CRB Monitor Securities Database Updates
During the week of March 20 - 26, 2023, CRB Monitor’s research team made several updates to securities’ information and added source documents & relevant news articles to the CRB Monitor database.
Summary of the updates for the Week of March 20 - 26, 2023:
|
Tier |
Total # |
Active / Inactive / Pre-IPO |
Added |
Removed |
Net Change |
|
Tier 1A |
145 |
121 / 22 / 2 |
+0 | -0 | +0 |
|
Tier 1B |
733 |
587 / 144 / 2 |
+1 | -0 | +1 |
|
Tier 2 |
342 |
320 / 18 / 4 |
+2 | -0 | +2 |
|
Tier 3 |
506 |
478 / 27 / 1 |
+2 | -0 | +2 |
|
Total Issuances |
1,726 |
1,506 / 211 / 9 |
+5 | -0 | +5 |
|
Total Issuers (w/o Pre-IPOs) |
1,301 |
- |
+2 | -0 | +2 |
|
Total Issuers (w/ Pre-IPOs) |
1,310 |
- |
+3 | -0 | +3 |
- Added 1 Tier 1B Security:
- +1 = New Security (Convertible Debt) Added to Existing Issuer: (“MediPharm Labs Corp.”)
- CUSIP = 58504DAA8
- ISIN = CA58504DAA87
- +1 = New Security (Convertible Debt) Added to Existing Issuer: (“MediPharm Labs Corp.”)
- Added 2 Tier 2 Securities:
- +1 = New CRB: (“Oxford Cannabinoid Technologies Holdings plc”)
- +1 = New CRB: (“Blackwell Intelligence Inc.”)
- Added 2 Tier 3 Securities:
- +2 = New CRB: (“PureTech Health plc”) – 1 Issuer with 2 Common Securities
All newly-identified CRBs during the week:
|
Company Name |
Tier |
Pure-Play | Sector |
Description |
| 2 | Yes | CBD - Pharma & Biotech | Oxford Cannabinoid Technologies Holdings plc is a UK-based pharmaceutical company developing a portfolio of prescription cannabinoid medicines. The Company has established a pipeline of three types of cannabinoid compounds, from which it is developing medicines that target the endocannabinoid system. OCTP's drug development pipeline, comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. | |
|
(Pre-IPO) |
2 | Yes | Media & Publishing | Blackwell Intelligence Inc. (Pre-IPO) is a start-up technology company which acquired cannabis assets from publicly-traded "Happy Belly Food Group Inc." (formerly "Plant & Co. Brands Ltd."). The assets consist of various educational websites/platforms relating to the cannabis industry designed to assist and educate people in their use of cannabis through the development of an online repository of cannabis-related information. Per Blackwell's own admission, "The company is currently a reporting issuer and has the intent to go public on the capital markets in due course." |
| 3 | No | CBD - Pharma & Biotech | PureTech Health plc is a US-based biotherapeutics/biopharma company engaged in the treatment paradigm for devastating diseases with a pipeline of various therapeutics and therapeutic candidates. Per its own admission, "A therapeutic candidate, LYT-310 (oral cannabidiol), is expected to enter the clinic in Q4 of 2023.“ Preclinical trials are currently underway with clinical trials expected to begin in Q4 of 2023. This is only one of many therapeutics/therapeutic candidates in the company’s pipeline, and the only one that is cannabis-related. |